Literature DB >> 23047780

The state of disparities in opportunistic infection prophylaxis for blacks with HIV/AIDS.

Christine U Oramasionwu1, Jim M Koeller, Kenneth A Lawson, Carolyn M Brown, Gene D Morse, Christopher R Frei.   

Abstract

OBJECTIVES: The purpose of this review is to identify and analyze published studies that have evaluated disparities for opportunistic infection (OI) prophylaxis between blacks and whites with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) in the United States.
METHODS: The authors conducted a web-based search of MEDLINE (1950-2009) to identify original research articles evaluating the use of OI prophylaxis between blacks and whites with HIV/AIDS. The search was conducted utilizing the following MeSH headings and search terms alone and in combination: HIV, AIDS, Black, race, ethnicity, disparities, differences, access, opportunistic infection, and prophylaxis. The search was then expanded to include any relevant articles from the referenced citations of the articles that were retrieved from the initial search strategy. Of the 29 articles retrieved from the literature search, 19 articles were excluded.
RESULTS: Ten publications met inclusion criteria, collectively published between 1991 and 2005. The collective time periods of these studies spanned from 1987 to 2001. Four studies identified a race-based disparity in that blacks were less likely than whites to use OI prophylaxis, whereas 5 studies failed to identify such a relationship between race and OI prophylaxis. One study identified disparities for Mycobacterium avium complex prophylaxis, but not for Pneumocystis jiroveci pneumonia prophylaxis.
CONCLUSIONS: The evidence regarding race-based disparities in OI prophylaxis is inconclusive. Additional research is warranted to explore potential race-based disparities in OI prophylaxis.

Entities:  

Mesh:

Year:  2012        PMID: 23047780      PMCID: PMC3470654          DOI: 10.1097/MLR.0b013e31826c85d1

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  39 in total

1.  Distrust, race, and research.

Authors:  Giselle Corbie-Smith; Stephen B Thomas; Diane Marie M St George
Journal:  Arch Intern Med       Date:  2002-11-25

2.  Disparities in antiretroviral prescribing for blacks and whites in the United States.

Authors:  Christine U Oramasionwu; Jeff Skinner; Laurajo Ryan; Christopher R Frei
Journal:  J Natl Med Assoc       Date:  2009-11       Impact factor: 1.798

Review 3.  Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature.

Authors:  Herminia Palacio; James G Kahn; T Anne Richards; Stephen F Morin
Journal:  Public Health Rep       Date:  2002 May-Jun       Impact factor: 2.792

4.  Underuse of primary Mycobacterium avium complex and Pneumocystis carinii prophylaxis in the United States.

Authors:  S M Asch; A L Gifford; S A Bozzette; B Turner; W C Mathews; K Kuromiya; W Cunningham; R Andersen; M Shapiro; A Rastegar; J A McCutchan
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-01       Impact factor: 3.731

5.  Late versus early testing of HIV--16 Sites, United States, 2000-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-06-27       Impact factor: 17.586

6.  Racial differences in the use of drug therapy for HIV disease in an urban community.

Authors:  R D Moore; D Stanton; R Gopalan; R E Chaisson
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245

7.  Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Authors:  Frank J Palella; Maria Deloria-Knoll; Joan S Chmiel; Anne C Moorman; Kathleen C Wood; Alan E Greenberg; Scott D Holmberg
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

8.  Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group.

Authors:  P J Easterbrook; J C Keruly; T Creagh-Kirk; D D Richman; R E Chaisson; R D Moore
Journal:  JAMA       Date:  1991-11-20       Impact factor: 56.272

9.  Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS.

Authors:  M A Fischl; G M Dickinson; L La Voie
Journal:  JAMA       Date:  1988-02-26       Impact factor: 56.272

10.  Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus.

Authors: 
Journal:  MMWR Suppl       Date:  1989-06-16
View more
  1 in total

1.  Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells.

Authors:  Ping Ma; Zhenwu Luo; Jing Qian; Zhongfang Yan; Lumin Zhang; Lisa Martin; Ziyu Wang; Huan Xia; Fangfang Yu; Wei Jiang
Journal:  Vaccine       Date:  2020-01-14       Impact factor: 3.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.